The U.S. FDA has granted Regenerative Medicine Advanced Therapy designation to KB707 for the treatment of advanced/metastatic ...

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies. In this episode, the panel provides an in-depth ...

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...

Sequential therapy strategies in oncogene-driven NSCLC. This figure illustrates a proposed therapeutic decision-making pathway for patients with NSCLC who develop acquired resistance after initial ...

More effective combinations of targeted therapies, strategies to minimize side effects, the use of subcutaneous rather than intravenous immunotherapies, and artificial intelligence (AI) tools to ...

A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

An expert discusses the personalized approach to treating ROS1-positive non-small cell lung cancer, emphasizing the preference for next-generation TKIs like taletrectinib and repotrectinib due to ...

DelveInsight's RET Fusion Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Use of neoadjuvant or perioperative immunotherapy in combination with chemotherapy has proven effective for some patients with non-small cell lung cancer (NSCLC), but its role in patients with EGFR- ...